The S&P 500 has experienced a challenging two-week period marked by escalating geopolitical tensions, sector rotation into defensives, and technical deterioration.
In light of this, below is a list of the top 10 S&P 500 healthcare holdings arranged according to their growth factor grade.
The list is topped by Eli Lilly and Company (LLY), with a growth grade of A. Intuitive Surgical, Inc. (ISRG) and Gilead Sciences, Inc. (GILD) follow in the rankings with grades of D+ and D, respectively.
Many of the remaining holdings, including Thermo Fisher Scientific Inc. (TMO), Abbott Laboratories (ABT), Merck & Co., Inc. (MRK), AbbVie Inc. (ABBV), and Johnson & Johnson (JNJ), carry lower growth grades of D-. The list concludes with Amgen Inc. (AMGN) and UnitedHealth Group Incorporated (UNH), both receiving growth grades of F.
The growth factor grade is a quantitative assessment used in stock analysis to evaluate a company’s growth prospects and expansion trajectory. This metric systematically analyzes multiple growth-related indicators to determine how effectively a company is scaling its business operations.
Growth factor grades are typically expressed on a letter scale (A+ through F), where higher grades indicate stronger growth characteristics relative to sector peers. An A+ grade represents exceptional growth potential, while lower grades suggest more moderate expansion or potential headwinds.
Here is the list:
- Eli Lilly and Company (LLY), Growth grade: A
- Intuitive Surgical, Inc. (ISRG), Growth grade: D+
- Gilead Sciences, Inc. (GILD), Growth grade: D
- Thermo Fisher Scientific Inc. (TMO), Growth grade: D-
- Abbott Laboratories (ABT), Growth grade: D-
- Merck & Co., Inc. (MRK), Growth grade: D-
- AbbVie Inc. (ABBV), Growth grade: D-
- Johnson & Johnson (JNJ), Growth grade: D-
- Amgen Inc. (AMGN), Growth grade: F
- UnitedHealth Group Incorporated (UNH), Growth grade: F